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a  b  s  t  r  a  c  t
Objective: To evaluate liver and spleen dimensions in childhood-onset systemic lupus ery-
thematosus (c-SLE) patients and healthy controls.
Methods: 30 c-SLE patients and 30 healthy control volunteers underwent abdominal ultra-
sound. The following two liver measurements were performed in left hepatic lobe:
craniocaudal and anteroposterior and three in right hepatic lobe (RHL): posterior cran-
iocaudal (PCC-RHL), anterior craniocaudal and anteroposterior. Three spleen dimension
measurements were also evaluated: longitudinal, transverse and anteroposterior. Demo-
graphic, clinical and laboratorial data, SLEDAI-2K, ECLAM, SLAM and treatment were
assessed.
Results: Mean current age was similar in c-SLE and controls (170.31 ± 27.81 vs. 164.15 ± 39.25
months; p = 0.486). The mean of PCC-RHL dimension was signiﬁcantly higher in c-SLE com-
pared to controls (13.30 ± 1.85 vs. 12.52 ± 0.93, p = 0.044). There were no differences between
the  other hepatic biometrics and splenic parameters (p > 0.05). Further analysis in c-SLE
patients according to PCC-RHL dimension ≥13.3 cm versus <13.3 cm showed that the median
of  SLEDAI-2K [8 (0–18) vs. 2 (0–8), p = 0.004], ECLAM [4 (0–9) vs. 2 (0–5), p = 0.019] and SLAM
[5  (1–13) vs. 2 (0–14), p = 0.016] were signiﬁcantly higher in patients with higher PCC-RHL
dimension, likewise the frequencie of nephritis (77% vs. 29%, p = 0.010). Liver enzymes were
similar in both groups (p > 0.05). Positive correlation was observed between SLEDAI-2K and
PCC-RHL (p = 0.001, r = +0.595). Negative correlation was evidenced between disease duration
and longitudinal dimension of spleen (p = 0.031, r = −0.394).
Conclusion: Our data raises the possibility that disease activity could lead to a subclinical
and  localized hepatomegaly during the disease course. Long disease duration resulted tospleen atrophy in c-SLE patients.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Biometria  do  fígado  e  do  bac¸o  em  pacientes  com  lúpus  eritematoso








r  e  s  u  m  o
Objetivo: Avaliar as dimensões do fígado e do bac¸o em pacientes com lúpus eritematoso
sistêmico de início pediátrico (LESp) e controles saudáveis.
Métodos: 30 pacientes com LES-i e 30 voluntários saudáveis controle foram submetidos
a  uma ultrassonograﬁa do abdome. Foram realizadas duas medic¸ões do fígado no lobo
hepático esquerdo (craniocaudal e anteroposterior) e três no lobo hepático direito (LHD)
(craniocaudal posterior [CCP-LHD], craniocaudal anterior e anteroposterior). Foram também
avaliadas três medidas das dimensões do bac¸o: longitudinal, transversal e anteroposterior.
Foram avaliados dados demográﬁcos, clínicos e laboratoriais, SLEDAI-2K, ECLAM, SLAM e
tratamento.
Resultados: A idade média foi semelhante nos pacientes com LES-i e controles (170,31 ± 27,81
vs.  164,15 ± 39,25 meses; p = 0,486). A média da dimensão CCP-LHD foi signiﬁcativamente
maior no grupo LES-i em comparac¸ão aos controles (13,30 ± 1,85 vs. 12,52 ± 0,93, p = 0,044).
Não  houve diferenc¸as nos outros parâmetros biométricos do fígado e do bac¸o  (p > 0,05). Uma
análise especiﬁca realizada apenas nos pacientes com LESp de acordo com a dimensão
CCP-LHD ≥13,3 cm versus <13,3 cm mostrou que a mediana do SLEDAI-2K [8 (0–18) vs. 2
(0–8), p = 0,004], ECLAM [4 (0–9) vs. 2 (0–5), p = 0,019] e SLAM [5 (1–13) vs. 2 (0–14), p = 0,016] era
signiﬁcativamente maior em pacientes com maior dimensão CCP-LHD, do mesmo  modo que
a  frequência de nefrite (77% vs. 29%, p = 0,010). As enzimas hepáticas foram semelhantes nos
dois grupos (p > 0,05). Foi observada uma correlac¸ão positiva entre o SLEDAI-2K e a dimensão
CCP-LHD (p = 0,001, r = +0,595). Evidenciou-se uma correlac¸ão negativa entre a durac¸ão da
doenc¸a  e a dimensão longitudinal do bac¸o  (p = 0,031, r = −0,394).
Conclusão: Os dados levantam a possibilidade de que a atividade da doenc¸a pode levar a
uma hepatomegalia subclínica e localizada durante o curso da doenc¸a. A durac¸ão da doenc¸a
resultou em atroﬁa do bac¸o em pacientes com LES-i.




















epatomegaly and/or splenomegaly occur in 20–50%
hildhood-onset systemic lupus erythematosus1 (c-SLE)
atients at disease onset, usually associated with disease
ctivity. Involvement of the reticuloendothelial system may
lso be associated with abnormal liver function tests.2,3
Abdominal ultrasound can be used to assess liver4 and
pleen measurements in children and adolescents with-
ut risk of radiation.5 However, a systematic evaluation
f these visceral organ dimensions has not been per-
ormed in c-SLE population, particularly during the disease
ourse.
Therefore, the objectives of our study were to evaluate liver
nd spleen dimensions in c-SLE patients and healthy controls
nd to assess possible associations between abnormalities in
iver and spleen sizes with demographic data, clinical features,
isease activity, cumulative damage and treatment.
aterials  and  methodsatients  and  controls
rom May to June 2012, 58 c-SLE patients were followed at our
ediatric Rheumatology Service. All of the patients fulﬁlledthe American College of Rheumatology criteria for c-SLE.6 The
exclusion criteria were current acute or chronic infections,
autoimmune hepatitis, other concomitant disease with hep-
atosplenomegaly, cancer or unwilling to participate. Out of
them, 15 were excluded due to current acute infections, 9 due
to unwillingness to participate and 4 due to autoimmune hep-
atitis. Therefore, the cross-sectional study was conducted in
30 c-SLE patients. The control group included 30 healthy con-
trol volunteers recruited from the primary care clinic nearby
our tertiary hospital. The control volunteers were submit-
ted to clinical evaluation, and liver and spleen biometrics.
Local ethics committee of our university hospital approved
this study, and informed consent was obtained from all par-
ticipants.
Liver  and  spleen  biometrics
Abdominal ultrasound was carried out by an experienced
and trained, specialist (SMS) using a 1–6 mHz  convex mul-
tifrequency transducer (LOGIC E9® – General Electric, USA).
The following two liver measurements were performed in
left hepatic lobe (LHL): craniocaudal (CC-LHL) and antero-
posterior (AP-LHL), and three in right hepatic lobe (RHL):
posterior craniocaudal (PCC-RHL), anterior craniocaudal (ACC-
RHL) and anteroposterior (AP-RHL). Three spleen dimension
 o l . 2
serum liver enzymes were similar in both groups (p > 0.05).
Only one c-SLE patient had hepatosplenomegaly (liver edge
4 cm below the right costal margin and spleen edge 4 cm
Table 1 – Demographic data, liver and spleen biometrics
in childhood-onset systemic lupus erythematosus









170.31 ± 27.81 164.15 ± 39.25 0.486
Female gender 23 (77) 19 (63) 0.398
BMI, kg/m2 21.15 (17.4–35.3) 22.1 (18.6–29.6) 0.721
BSA, m2 1.56 (0.94–2.02) 1.49 (1.32–2.03) 0.875
Liver biometrics
CC-LHL, cm 7.73 ± 1.48 7.57 ± 1.21 0.648
AP-LHL, cm 5.22 ± 0.79 5.38 ± 0.68 0.405
PCC-RHL, cm 13.30 ± 1.85 12.52 ± 0.93 0.044
ACC-RHL, cm 8.33 ± 1.27 8.25 ± 1.04 0.698




9.85  (7.0–16.9) 9.50 (8.1–11.9) 0.387
Transverse, cm 3.50 (2.8–5.8) 3.75 (2.0–6.0) 0.524
AP, cm 6.70 ± 1.09 6.64 ± 0.85 0.793
Results are presented in median (range) or mean ± standard devia-
tion and n (%).
BMI, body mass index; BSA, body surface area; CC, craniocaudal;348  r e v b r a s r e u m a t
measurements were also evaluated: longitudinal, transverse
and anteroposterior.
Demographic  data,  clinical,  laboratorial  and  treatment
assessment
Demographic data included current age, disease duration
and gender.  Weight and height were evaluated. Body mass
index (BMI) was deﬁned by weight in kilograms/height in
meters2 (kg/m2). Body surface area (BSA in m2) was calculated
according to the formula: (weight in kilograms0.425 × height in
centimeters0.725) × 0.007184.
SLE clinical manifestations were deﬁned as: hepatomegaly
(liver edge >2 cm below the right costal margin), splenomegaly
(palpable spleen below the left costal margin), mucocu-
taneous lesions (malar or discoid rash, oral ulcers or
photosensitivity), articular involvement (non-erosive arthri-
tis), neuropsychiatric disease (seizure or psychosis), renal
involvement (proteinuria ≥ 0.5 g/24 h, presence of cellular
casts, and/or persistent hematuria ≥ 10 red blood cells per high
power ﬁeld), serositis (pleuritis or pericarditis), and hema-
tologic abnormalities (hemolytic anemia, leukopenia with a
white blood cell count < 4000 mm–3, lymphopenia < 1500 mm–3
on two or more  occasions and thrombocytopenia with
platelet count < 100,000 mm–3 in the absence of drugs or
infection).
Disease activity was evaluated according to SLE Disease
Activity Index 2000 (SLEDAI-2K),7 European Consensus Lupus
Activity Measurement (ECLAM),8 and Systemic Lupus Activ-
ity Measure (SLAM) scores.9 Cumulative damage using the
SLE International Collaborating Clinics/ACR Damage Index
(SLICC/ACR-DI).10
Erythrocyte sedimentation rate (ESR) was performed
by Westergreen method and C-reactive protein (CRP) by
nephelometry. Anti-double-stranded DNA (anti-dsDNA) was
detected by indirect immunoﬂuorescence using Crithidia lucil-
iae as substrate. Presence of anticardiolipin antibodies (aCL)
IgG and IgM was analyzed by enzyme-linked immunosor-
bent assay (ELISA). Lupus anticoagulant (LAC) was detected
according to the guidelines of the International Society on
Thrombosis and Hemostasis.11
Data concerning the cumulative and current dosage of
prednisone, hydroxychloroquine, methotrexate, azathioprine,
intravenous cyclophosphamide, cyclosporine and mycophe-
nolate mofetil were determined.
Statistical  analysis
Results were presented as the mean ± standard deviation (SD)
or median (range) for continuous and number (%) for cate-
gorical variables. Data were compared by Mann–Whitney test
in continuous variables to evaluate differences among c-SLE
and control group, and among SLE subgroups. For categori-
cal variables, differences were assessed by Fisher’s exact test.
Spearman rank correlation coefﬁcient was used for correla-
tions between disease activity scores and liver and spleen
parameters. The level of signiﬁcance of independent variable
was set at 5% (p < 0.05). 0 1 5;5 5(4):346–351
Results
Table 1 includes demographic data, liver and spleen biomet-
rics in c-SLE patients and healthy controls. The mean current
age was similar between the c-SLE and controls (170.31 ± 27.81
vs. 164.15 ± 39.25 months; p = 0.486), likewise the frequency
of female gender (77% vs. 63%, p = 0.398) and median of
BSA (p = 0.875). The mean of PCC-RHL dimension was sig-
niﬁcantly higher in c-SLE compared to controls (13.30 ± 1.85
vs. 12.52 ± 0.93, p = 0.044) (Table 1). There were no differences
between the other hepatic biometrics and splenic parameters
(p > 0.05). None of c-SLE and healthy controls had jaundice,
ascites, pruritus, bleeding, liver or spleen thrombosis or sono-
graphic hepatic steatosis.
Further analysis in c-SLE patients according to PCC-
RHL dimension ≥13.3 cm (Table 2) (mean of this biometric
measurement in 30 c-SLE patients) versus <13.3 cm showed
that the median of SLEDAI-2K [8 (0–18) vs. 2 (0–8), p = 0.004],
ECLAM [4 (0–9) vs. 2 (0–5), p = 0.019] and SLAM [5 (1–13)
vs. 2 (0–14), p = 0.016] were signiﬁcantly higher in patients
with higher PCC-RHL dimension, likewise the mean of ESR
(33.7 ± 16 vs. 22.0 ± 13 mm/h, p = 0.038). The frequencies of
nephritis were signiﬁcantly higher in patients with PCC-RHL
dimension ≥13.3 cm versus <13.3 cm (77% vs. 29%, p = 0.010).
The mean of BSA was also signiﬁcantly higher in the former
group (1.56 ± 0.23 vs. 1.37 ± 0.26m2, p = 0.043). The median ofLHL, left hepatic lobe; AP, anteroposterior; PCC, posterior cranio-
caudal; RHL, right hepatic lobe; ACC, anterior craniocaudal.
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Table 2 – Demographic data, disease parameters, clinical and laboratorial features and treatment in childhood-onset








Current age, month 173.49 ± 23.05 167.87 ± 31.45 0.592
Disease duration, month 36.0 (7.2–104.4) 40.8 (4.8–156.0) 0.869
BMI, kg/m2 21.1 (17.4–35.3) 21.4 (16.9–32.9) 0.483
BSA, m2 1.56 ± 0.23 1.37  ± 0.26 0.043
Female gender 11 (85) 12  (71) 0.326
Disease parameters
SLEDAI-2K 8 (0–18) 2 (0–8) 0.004
ECLAM 4 (0–9) 2 (0–5) 0.019
SLAM 5 (1–13) 2 (0–14) 0.016
SLICC-ACR-DI 0 (0–1) 0 (0–1) 0.242
Clinical and laboratorial features
Hepatosplenomegaly 0 (0) 1 (6) 1.0
Articular 2 (15) 3 (18) 0.633
Mucocutaneous 6 (46) 6 (35) 0.547
Hematological 5 (38) 4 (23) 0.314
Serositis 1 (8) 1 (6) 0.687
Neuropsychiatric 2 (15) 0 (0) 0.179
Nephritis 10 (77) 5 (29) 0.010
ESR, mm/h 33.7 ± 16 22.0 ± 13 0.038
CRP, mg/dL 7.4 (0.1–20.8) 0.8 (0.1–12.9) 0.094
AST, IU/L 20 (11–55) 21 (11–63) 0.322
ALT, IU/L 31 (11–47) 33 (7–61) 0.622
Anti-dsDNA 3 (23) 0 (0) 0.070
IgM ACL 3 (23) 1 (6) 0.204
IgG ACL 3 (23) 2 (12) 0.367
LAC 0 (0) 2 (12) 0.313
Treatment
Current prednisone 12 (92) 12 (71) 0.156
Dose, mg/day 20 (10–50) 15 (3–30) 0.089
Cumulative dose, g 24.85 (7.1–54.5) 19.72 (6.1–451.3) 0.477
Current azathioprine 4 (31) 7 (41) 0.421
Current mycophenolate mofetil 7 (54) 4 (23) 0.093
Current methotrexate 2 (15) 2 (12) 0.591
Current hydroxychloroquine 11 (85) 17 (100) 0.179
Results are presented in median (range) or mean ± standard deviation and n (%).
BMI, body mass index; BSA, body surface area; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; ECLAM, European
















since these parameters may inﬂuence these organs sizes. Theing Clinics/ACR Damage Index; AST, alanine aminotransferase; ALT
anticoagulant.
elow the left costal margin), however the PCC-RHL was
13.3 cm.
Correlations were evidenced between SLEDAI-2K and PCC-
HL (p = 0.001, r = +0.595), SLEDAI-2K and CC-LHL (p = 0.015,
 = +0.440), SLEDAI-2K and ACC-RHL (p = 0.017, r = +0.431), and
LEDAI-2K and AP-RHL dimensions (p = 0.029, r = +0.399), as
ell as observed between SLEDAI-2K and longitudinal spleen
imension (p = 0.042, r = +0.373). Also, it was found a positive
orrelation between SLAM and PCC-RHL (p = 0.020, r = +0.422),
LAM and CC-LHL (p = 0.047, r = +0.365), ECLAM and PCC-RHL
p = 0.018, r = +0.430), ECLAM and CC-LHL (p = 0.008, r = +0.475),
s well as found between ECLAM and longitudinal spleen
imension (p = 0.047, r = +0.365).Negative correlation was evidenced between disease
uration and longitudinal dimension of spleen (p = 0.031,
 = −0.394).artate aminotransferase; ACL, anticardiolipin antibody; LAC, lupus
Discussion
To our knowledge, this was the ﬁrst study that speciﬁcally
addressed liver and spleen biometrics in pediatric lupus popu-
lation, and showed subclinical hepatomegaly in patients with
disease activity associated with BSA. Moreover, long period of
disease duration may be related to splenic atrophy in c-SLE
patient.
The great advantage of the present study design was the
systematic assessment of various liver and spleen dimen-
sions in c-SLE patients and healthy controls. The similar age,
gender and BSA in c-SLE and control groups were relevant,
5rigorous selection criteria of our patients and controls with-
out infections, cancer,12 autoimmune hepatitis,2,13 and other
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concomitant chronic diseases with hepatosplenomegaly are
important since these abnormalities may also inﬂuence the
dimensions. However, the main limitations of this study were
the small number of patients, the lack of laboratory exams
evaluation in control group and the lack of assessement of
splenic function, since c-SLE patients could present functional
asplenia.14
Hepatomegaly is a common ﬁnding at disease onset in
c-SLE patients and adult SLE.2,3,15 During disease course,
liver enlargement in lupus patients, either children or adults,
may be associated with hepatic congestion, fatty inﬁltration,
autoimmune and viral hepatitis, metabolic disorders, throm-
bosis or hepatotoxic drugs usage.2,15,16
Our patients had localized right-liver hypertrophy asso-
ciated with disease activity, suggesting the same systemic
pathogenesis mechanism. These patients had mild and sub-
clinical liver enlargement probably due to liver congestion,
liver chronic inﬂammation and hypervascularization. Of note,
this enlargement was associated with severe disease and
correlated with various clinical and laboratory disease param-
eters. Indeed, the autopsy registry data of the liver showed
that hepatic congestion, liver chronic inﬂammation and/or
liver arteritis were observed in 77% of adult and c-SLE patients
and may be reﬂecting lupus activity.15 Positive correlation was
also found between disease activity parameters and longitu-
dinal spleen dimension, despite the absence of clinical and
sonography splenomegaly.
Damage to hepatocyte cell seems not to be relevant herein,
since none of our patients had elevated levels of liver enzymes.
Moreover, corticosteroid use, a known cause of hepatomegaly
and fatty liver disease, may have not contributed to enlarge-
ment of this organ in the present study.2,15
Both pediatric and adult SLE patients may present splenic
atrophy.14,17 Importantly, our children and adolescent lupus
patients with long disease duration presented spleen size
reduction, thus indicating splenic atrophy during the dis-
ease course. A previous study evaluating adult SLE patients
found that splenic atrophy had no correlation with disease
duration.17 However, the mechanisms of spleen atrophy and
functional asplenia are still not clear in pediatric and adult SLE
populations and further studies will be necessary.
In conclusion, our data raises the possibility that disease
activity could lead to subclinical and localized hepatomegaly.
We  hypothesize that liver is a potential target organ for
active lupus during the disease course. Long disease duration
resulted to spleen atrophy in c-SLE patients.
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